Status:

RECRUITING

A Chatbot to Support Substance Use Recovery

Lead Sponsor:

Dimagi Inc.

Collaborating Sponsors:

National Institute on Drug Abuse (NIDA)

University of California, Los Angeles

Conditions:

Opiate-Related Disorders

Opiate Substitution Treatment

Eligibility:

All Genders

18-65 years

Phase:

PHASE1

PHASE2

Brief Summary

The goal of this clinical trial is to learn if/how an AI chatbot can support patients who in recovery for substance use, specifically those who are receiving medication for opioid use disorder. Can t...

Eligibility Criteria

Inclusion Criteria:

  • 18-65 years old
  • Comfortable with reading, understanding, and communicating in English
  • Receiving medication treatment for OUD at MGH?
  • Able to participate in a remote interview?
  • Own or have reliable access to Wi-Fi or a cellular network
  • Willing to use a mobile device to access the chatbot?

Exclusion Criteria:

  • Has any cognitive, visual, or auditory impairments that may prevent the participant from using the chatbot on a mobile device?
  • Unstable medical condition that compromises the ability to safely participate

Key Trial Info

Start Date :

March 7 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

September 1 2025

Estimated Enrollment :

55 Patients enrolled

Trial Details

Trial ID

NCT06845878

Start Date

March 7 2025

End Date

September 1 2025

Last Update

March 12 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Massachusetts General Hospital

Boston, Massachusetts, United States, 02114